Alexion Pharmaceuticals, Inc. (ALXN): Price and Financial Metrics
Alexion Pharmaceuticals, Inc. (ALXN)
Today's Latest Price: $112.30 USD
Updated Jul 2 4:00pm
Add ALXN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ALXN Stock Summary
- ALXN has a market capitalization of $24,785,670,855 -- more than approximately 92.62% of US stocks.
- Over the past twelve months, ALXN has reported earnings growth of 352.94%, putting it ahead of 96.24% of US stocks in our set.
- In terms of volatility of its share price, ALXN is more volatile than only 6.58% of stocks we're observing.
- Stocks that are quantitatively similar to ALXN, based on their financial statements, market capitalization, and price volatility, are KLAC, GRMN, YNDX, BILI, and IQ.
- Visit ALXN's SEC page to see the company's official filings. To visit the company's web site, go to www.alexion.com.
ALXN Stock Price Chart Technical Analysis Charts
ALXN Price/Volume Stats
| Current price | $112.30 | 52-week high | $134.84 |
| Prev. close | $112.39 | 52-week low | $72.67 |
| Day low | $111.72 | Volume | 1,283,159 |
| Day high | $114.49 | Avg. volume | 2,405,032 |
| 50-day MA | $108.98 | Dividend yield | N/A |
| 200-day MA | $103.79 | Market Cap | 24.80B |
Alexion Pharmaceuticals, Inc. (ALXN) Company Bio
Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.
ALXN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $112.30 | $380.65 | 235% |
We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 73th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 236.67%. In terms of the factors that were most noteworthy in this DCF analysis for ALXN, they are:
- The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 20.88% of the free cash flow producing stocks we're observing.
- ALXN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 41.52% of tickers in our DCF set.
- As a business, Alexion Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 228% |
| 1% | 232% |
| 2% | 235% |
| 3% | 238% |
| 4% | 242% |
| 5% | 245% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ALXN, try PCRX, CI, INVA, SEM, and LXRX.
Loading social stream, please wait...